Filana Therapeutics adds biopharma executive Jill Quigley to board
The Austin-based company named Quigley a Class I director as it prepares to begin a Phase 2a study of simufilam in TSC-related epilepsy.
Filana Therapeutics, Inc. (NASDAQ: FLNA) appointed Jill M. Quigley to its Board of Directors effective November 8, 2026, according to an 8-K filed with the SEC. Quigley was appointed as a Class I director and will serve a term expiring at the company's 2028 annual meeting of stockholders.1 She has not been named to any board committees.1 The filing states there were no arrangements between Quigley and any other person related to her appointment, and that she has no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.1
Filana is developing simufilam for treatment of TSC-related epilepsy. CEO Rick Barry said the company is preparing for a planned Phase 2a clinical study of simufilam in TSC-related epilepsy, with patient screening expected to begin by the first quarter of 2027.1
Quigley's background spans legal, operations, and executive roles in biotech. She has served as chief executive of a preclinical biotechnology company since November 2026, and before that held a position described as entrepreneur in residence at J.P. Morgan Life Sciences Private Capital, from November 2025 to November 2026.1 She was a director of Terns Pharmaceuticals, Inc. from December 2020 until its acquisition by Merck in May 2026, and served on an interim basis as a senior advisor and strategy officer there from October 2023 through February 2024.1 She also served on the board of Chemomab Therapeutics Ltd. from 2022 to 2026.1 Earlier, she was CEO of Genuiti Therapeutics, Inc. from September 2023 to June 2025, and before that was Chief Operating Officer at Passage Bio, Inc. from November 2018 to December 2021.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.